Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul 2;8(7):ofab351.
doi: 10.1093/ofid/ofab351. eCollection 2021 Jul.

Safety of Tedizolid as Suppressive Antimicrobial Therapy for Patients With Complex Implant-Associated Bone and Joint Infection due to Multidrug-Resistant Gram-Positive Pathogens: Results From the TediSAT Cohort Study

Tristan Ferry  1   2   3 , Anne Conrad  1   2   3 , Eric Senneville  4   5   6 , Sandrine Roux  1   2 , Céline Dupieux-Chabert  1   2   3 , Aurélien Dinh  7   8 , Sébastien Lustig  2   9 , Sylvain Goutelle  1   2   10 , Thomas Briot  1   2 , Truong-Thanh Pham  1   2   11 , Florent Valour  1   2   3
Affiliations

Safety of Tedizolid as Suppressive Antimicrobial Therapy for Patients With Complex Implant-Associated Bone and Joint Infection due to Multidrug-Resistant Gram-Positive Pathogens: Results From the TediSAT Cohort Study

Tristan Ferry et al. Open Forum Infect Dis. .

Abstract

A prospective cohort study was conducted to evaluate long-term safety of tedizolid as suppressive antimicrobial treatment in patients with implant-associated bone and joint infection caused by multidrug-resistant gram-positive pathogens. Seventeen patients received tedizolid with a median duration of treatment of 6 months. No patients developed a serious adverse event.

Keywords: bone and joint infection; linezolid; periprosthetic joint infection; suppressive antimicrobial therapy; tedizolid.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Evolution of hemoglobin (A), platelet count (B), white blood cell (WBC) count (C), and neutrophil count (D) during the first 12 months of suppressive antimicrobial therapy with tedizolid.
See this image and copyright information in PMC

References

    1. Fang C, Wong TM, Lau TW, et al. Infection after fracture osteosynthesis—part I. J Orthop Surg (Hong Kong) 2017; 25:2309499017692712. - PubMed
    1. Prendki V, Ferry T, Sergent P, et al. Prolonged suppressive antibiotic therapy for prosthetic joint infection in the elderly: a national multicentre cohort study. Eur J Clin Microbiol Infect Dis 2017; 36:1577–85. - PubMed
    1. Titécat M, Senneville E, Wallet F, et al. Bacterial epidemiology of osteoarticular infections in a referent center: 10-year study. Orthop Traumatol Surg Res 2013; 99:653–8. - PubMed
    1. Douros A, Grabowski K, Stahlmann R. Drug-drug interactions and safety of linezolid, tedizolid, and other oxazolidinones. Expert Opin Drug Metab Toxicol 2015; 11:1849–59. - PubMed
    1. Ferry T, Batailler C, Conrad A, et al. Correction of linezolid-induced myelotoxicity after switch to tedizolid in a patient requiring suppressive antimicrobial therapy for multidrug-resistant Staphylococcus epidermidis prosthetic-joint infection. Open Forum Infect Dis 2018; 5:ofy246. - PMC - PubMed